Page 19 - Read Online

Page 314 Ong et al. Neuroimmunol Neuroinflammation 2020;7:311-8 I http://dx.doi.org/10.20517/2347-8659.2020.05

1
3
2
5
8
6
7
4
Pt
53
41
61
31
41
30
43
56
Age
therapy.
F
F
F
F
F
M
M
M
RESULTS
Sex
6
3
8
11
13
17
10
10
Dis
dur
(yrs)
+
+
+
+
+
+
+
+
ab
Statistical analysis
AQP4
1
-
3
3
3
7
9
10
ON
1
1
1
3
4
2
before RTX
2
7
TM
Number of relapses
+
+
+
+
+
+
+
+
AZA
-
-
-
-
-
-
+
+
MMF
-
-
-
-
-
RTX
-
+
+
MTX
-
-
-
-
-
INF
IVIg
IVIg
Cyclo
alii
beta-1a
Prior ISS received before
3
3
3
7
3
4
10
0.5
before
Dis dur
RTX (yrs)
1
3
5
0.3
3.7
2.2
0.7
0.6
prior to
RTX (yrs)
Dur of ISS
transverse myelitis manifestations and all of them were AQP4 antibody positive.
3.5
7.0
9.0
5.0
4.0
6.5
2.0
6.5
RTX
Pre
Table 1. Characteristics of 8 neuromyelitis optica spectrum disorder patients treated with rituximab
EDSS
2.5
9.0
2.0
4.5
2.0
2.0
6.5
1.0
(6 mo)
TBNK: T-cell, B-cell and NK cell; bd: twice a day; od: once daily; pred: prednisolone; -: negative; NIL: nothing; +: positive
Post RTX
1.0
2.5
1.0
1.0
1.0
6.5
9.0
4.0
(1 yr)
EDSS
Post RTX
1.3
1.7
1.3
1.4
1.0
0.6
3.0
4.0
RTX
Pre
differences between pre and post treatment in patients with NMOSD. P value < 0.05 was taken as significant.
0
0
0
0
0
0
ARR (yrs)
0.1
0.1
RTX
Post
4
3
5
4
4
2
4
3
Pre
RTX
mRS
5
3
2
1
2
2
2
4
RTX
Post
6
2
5
2
7
6
4
6
Post
(yrs)
RTX f/up
1%
%
NA
3%
NA
NA
NA
NA
NA
B cell
TBNK
MMF 1 g bd
RTX
Pred 5 mg od
Pred 5 mg od
Pred 5 mg od
Pred 10 mg od
AZA 50 mg od
AZA 50 mg od
AZA 125 mg od
AZA 100 mg od
AZA 100 mg od
MTX 5 mg weekly
Maintenance post
MMF (two patients) or methotrexate (two patients) [Table 1]. The patients had an average of 5 optic neuritis and 2 transverse myelitis relapses prior to RTX
characteristics are listed in Table 1. The mean duration of disease prior to RTX was 4.1 years (SD = 2.9). Our cohort of patients mostly had optic neuritis or
From January 2008 to May 2018, 8 out of 194 patients (4.1%) with NMOSD in our hospital database received a single course of RTX infusion. The mean
azathioprine; MMF: mycophenolate mofetil; MTX: methotrexate; IVIg: intravenous immunoglobulin; ARR: annualized relapsed rate; mRS: modified rankin scale; EDSS: expanded disability status scale;
Pt: patient; Dis: disease; dur: duration; yrs: years; mo: month; alii: others; AQP4 ab: aquaporin 4 antibody; RTX: rituximab; ON: optic neuritis; TM: transverse myelitis; ISS: immunosuppressants; AZA:
Data collected was analyzed using SPSS version 24 software, to look at descriptive data; means, medians, percentages and Wilcoxon signed rank test for
All patients had previously received immunosuppressants for a mean duration of 2 years (SD = 1.7) prior to RTX; they were either on AZA (eight patients),
age of disease onset was 44.5 years (SD = 11). Six (75%) of them were female, with a female to male ratio of 3:1. The patient’s demographic and clinical